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Low molecular weight chemical (LMW) allergens are commonly referred to as haptens. Haptens must complex with proteins to
be recognized by the immune system. The majority of occupationally related haptens are reactive, electrophilic chemicals, or are
metabolized to reactive metabolites that form covalent bonds with nucleophilic centers on proteins. Nonelectrophilic protein
binding may occur through disulﬁde exchange, coordinate covalent binding onto metal ions on metalloproteins or of metal
allergens, themselves, to the major histocompatibility complex. Recent chemical reactivity kinetic studies suggest that the rate
of protein binding is a major determinant of allergenic potency; however, electrophilic strength does not seem to predict the
ability of a hapten to skew the response between Th1 and Th2. Modern proteomic mass spectrometry methods that allow detailed
delineation of potential diﬀerences in protein binding sites may be valuable in predicting if a chemical will stimulate an immediate
or delayed hypersensitivity. Chemical aspects related to both reactivity and protein-speciﬁc binding are discussed.
1.Introduction
The term, “hapten,” was coined by Landsteiner and Jacobs
[1] and is derived from the Greek “hapten”, meaning “to
fasten.” Haptens are low molecular weight (LMW; <1000
daltons) chemicals that must bind to a carrier molecule to be
antigenic. The carrier is usually an endogenous or exogenous
proteintowhichtheLMWchemicaliscovalentlybound.The
hapten hypothesis was originally proposed to explain both
humoral and cellular immune responses to LMW chemicals
observed by Landsteiner and Jacobs [1] in their research.
The absolute requirement for covalent binding of a hapten
to a protein for immune recognition in the development
of all drug/LMW chemical allergies has been challenged in
recent years [2], but substantial evidence exists for this to be
a prominent mechanism throughwhichchemicalsand drugs
or their metabolites become antigenic.
T h er o l eo fc h e m i c a lr e a c t i v i t yh a sb e e np r o p o s e dt ob e
one of the major determinants in allergic contact dermatitis
(ACD). Over the years, extensive databases containing rep-
resentative chemicals that are skin sensitizers have been pub-
lished[3–5].Inthecontextofoccupationalhealth,predictive
toxicology, and ensuring overall safety of manufactured
products, it is important that skin sensitization potential
of new and existing chemicals be assessed. The use of
guinea pigs has been the experimental model of choice
in evaluating the skin sensitization potential of chemicals
[6, 7] until about a decade ago when the local lymph node
assay (LLNA) was adopted after extensive interlaboratory
validation [8].
Although ACD is a Type IV hypersensitivity response,
the ability of a chemical to bind to macromolecules is also
thought to be important for immediate (Type I) hyper-
sensitivity sensitization and reactions in both the skin and
lung. Presently, why a speciﬁc LMW chemical predominately
skews the immune system toward Type I versus Type
IV hypersensitivity is not known. Electrophilic reactivity
alone does not seem to distinguish respiratory and dermal
sensitizerssuchastoluenediisocyanateanddichlorobenzene,
respectively. Selective protein targets or sites on a protein
may be important and recent advances in protein mass
spectrometric analysis now provide the capability to better
explore how and where such chemicals bind. The present
paper discusses these physical chemical aspects related to
formation of the hapten-carrier protein complex.2 Journal of Allergy
2.ElectrophilesandReactivity
The hapten hypothesis was developed from the interaction
of nucleophilic moieties on proteins with chemicals that
are electrophilic. Adduct formation has been demonstrated
to be more feasible with electrophilic chemicals [9]. In
the following description, haptenation within the skin is
discussed, as most of the research knowledge gained has
been through examining the relationship between chemical
reactivity and allergenicity in this organ system. An analysis
of two published databases [4, 5] containing more than
300 chemicals demonstrated to be allergens by the LLNA
reveals that approximately 40% of the skin sensitizers have at
least an electrophilic center that is amenable to nucleophilic
attack. From an organic chemistry perspective, formation of
such adducts is via covalent bonds and to a certain extent
coordination bonds. This is chieﬂy because covalent and
coordination bonds have bond energies ranging from 200
to 420kJ/mol compared to hydrophobic, dipolar, and ionic
interactions with bond energies <50kJ/mol. The high bond
energies enable covalent adducts to survive the intracellular
antigen processing of the haptenated protein into short
peptides for cell surface expression by MHC complexes.
Both guinea pig ACD models and LLNA data have been
used to develop a number of structural-activity-relationship
models relating chemical reactivity and hydrophobicity
to skin sensitization potency [10]. Hapten reactivity data
generated from our laboratory [11]s u p p o r t sac e n t r a lr o l e
forchemicalreactivityinallergicsensitization.Reactivityrate
constants (k) were obtained for twenty ﬁve electrophilic hap-
tens using a thiol-based probe, 4-nitrobenzenethiol (NBT).
This k is a measure of the speed at which an electrophilic
hapten will bind to a nucleophilic center. A very high
correlation was obtained between allergic potency (EC3) of
electrophilic haptens as determined by the LLNA and the
reactivity rate constants (r2 = 0.74, independent of reactivity
domain). More recently, we have developed a similar assay
using an amine-based probe, and preliminary results suggest
that a similar relationship between EC3 and reactivity with a
nucleophilic amine exists [12].
Employing chemical reactivity as an endpoint to probe
target toxicity is neither restricted to skin sensitization nor
is it a new concept. For example, the ability of a chemical
to react with biomolecules has been used as a predictor for
aquatictoxicity[13,14]andcarcinogenesis[15].Landsteiner
andJacobs[1]notedcorrelationsbetweenachemical’sability
to cause skin sensitization in guinea pigs with its reactivity to
aniline [1]. Interestingly, Landsteiner and Jacobs optimized
their chemical reactions by altering pH or elevating the
reaction temperature to observe reaction to nucleophiles like
butylamineandaniline.Ithastobenotedthatmanycovalent
adducts that would otherwise form under harsh conditions
are not formed as reaction conditions (i.e., temperature, pH)
and medium are adjusted to physiological-like conditions.
More recently, reactivity assays utilizing cysteine, lysine,
glutathione,andseveralmodelpeptideshavebeendeveloped
and eﬀorts are underway to validate them as alternative
in chemico methods for screening skin sensitizers [16–19].
The underlying concept for all these assays is electrophile-
nucleophile interaction.
An understanding of the chemistry of electrophiles is
required to produce qualitative and quantitative data and
also for determination of an appropriate solvent system
for reactivity assessment. For example, cinnamic aldehyde
(EC3 = 3; [20]) and bromohexadecane (EC3 = 1.75; [21])
which are both moderate sensitizers in the LLNA require
diﬀerent solvent systems (in vivo, in vitro, and in chemico)
for assessment of allergenicity. While all chemicals with
reactive electrophilic centers will form covalent adducts with
proteins, mechanistic pathways are diﬀerent for diﬀerent
chemicals and may determine the type and strength of
adduct formed. Table 1 illustrates the ﬁve common mech-
anistic domains and the electrophilic centers amenable to
nucleophilic attack. An extensive analysis of mechanistic
domains, their subcategories, and “special cases (domain not
clearly deﬁned or >1 domain for a single chemical)” has
been discussed in recent reviews [9, 22, 23]. Mechanistic
domains for protein interaction should not be confused with
chemical classes, which are structural-based classiﬁcations.
Mechanistic domains are functional reaction groups that are
targeted as alerting pointers to a chemical’s possible reaction
with a protein and thus classify chemicals based on their
reaction chemistry. For example, benzoquinone and 2,3-
butanedione are both ketones but they belong to the Michael
acceptor (MA) and Schiﬀ base former (SBF) mechanistic
domains, respectively.
Use of chemical classes instead of mechanistic domains
has been noted to have a number of limitations. The
relative alkylation index (RAI) of Roberts and Williams was
developed using chemical classes and could only predict
reactions of a select group of chemical classes [24]. When
the RAI was modiﬁed to predict protein haptenation based
on mechanistic domains, it attained applicability to a
wider range of chemicals as discussed by Patlewicz et al.
[10]. Our initial experience with 19 chemicals spanning
three mechanistic domains (MA, SN1/SN2, AA) suggests
that restricting correlations between k and LLNA data to
mechanistic domains was not necessary to provide a good
prediction of an electrophilic hapten’s allergenic potency
[11]. Despite a good prediction of allergenic potency that
was obtained across all binding mechanisms, separation of
allergens by mechanistic domain improved the correlations
from linear regression analysis. A further comparison of MA
and SN1/SN2 to EC3 by regression analysis reveals similar
slopes, but diﬀerent Y-intercepts (P = .006), conﬁrming
that the mechanism of electrophilic binding does inﬂuence
allergenic potency.
3.HaptenBioavailabilityandReactivity
Methods Development
Another major physical chemical consideration involves
the bioavailability of the hapten. For skin, this is pene-
tration of the chemical across the stratum corneum and
is thought to be mainly a function of the chemical’s
solubility (octanol/water partitioning; logP). Models for
prediction of skin sensitization take this into considerationJournal of Allergy 3
Table 1: Common mechanistic domains.
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and usually include both reactivity and hydrophobicity
parameters. While the inclusion of penetration rate may be
ideal for accurate prediction of skin sensitization potential,
inpractice,itisnotasigniﬁcantparameter[11,25]ashapt e n
reactivity rates alone highly correlate with LLNA potency.
Most electrophilic haptens tested in our model fall into the
desired range of logP values (−1 . 4t o4 )f o rs k i na b s o r p t i o n
and lipophilicity. It is possible that bioavailability may exert
a greater inﬂuence on allergenic potency for extremely
hydrophilic and lipophilic haptens. Roberts and Natsch [26]
included both reactivity and hydrophobicity parameters in
their modeling of allergenic potency and noted that the
inﬂuence of reactivity was greater than that of solubility for
predicting allergenic potency.
Methods for the assessment of electrophilic chemical
allergen binding to (protein) nucleophiles developed in
recent years have been primarily non-kinetic-based assays
that measure the loss of the unconjugated nucleophile.
Development of these methods is based on the assump-
tion that hapten bioavailability for chemicals with logP
values between −1.4 and 4 is approximately the same. The
nucleophilic probes reported include glutathione [16, 18,
27] or model peptides with a free cysteine thiol or lysine
amine [17, 28]. These assays report percent depletion as the
reactivityindexforagivenchemical.Therationalefordesign
of a particular synthetic peptide, including the choice of
neighboring amino acids in the hepta-peptides and why only
seven amino-acid peptides are used, has not been delineated
for most of the peptide probes proposed. The exception is
the peptide, Ac-NKKCDLF (Cor1-C420) [29], derived from
AA417-423 of the human Coronin 1 protein, where the
Cys420 is thought to be highly reactive to electrophiles [30].
The original HPLC-based peptide reactivity assay has since
had numerous modiﬁcations and improvements including
the inclusion of LC-MS to characterize the adducts [29,
31] and conﬁguring it to high throughput kinetic proﬁling
for more accurate determination of rate constants [26].
The modiﬁcations seek to interrogate the chemistry behind
the peptide depletion by the electrophilic skin sensitizers
and also begin to move towards high throughput assay
development. The generation of reaction kinetics data was
another important aspect that had been lacking in the
original peptide reactivity assay. Data on peptide depletion
based on varying initial electrophile concentrations [26]
resultsinmoreaccuratedeterminationofreactivityconstants
as opposed to derivation of the RC50 (2h assay) [18,
27] and peptide depletion (24h assay) [32]a sr e a c t i v i t y
indices. These endpoint determinations do not adequately
capture the nature of the chemical kinetics involved in these
electrophile-nucleophile interactions. The fact that values
are measured at ﬁxed time points under pseudo-ﬁrst-order
conditions (electrophile   peptide) is a limitation of these
assays. Fixed time points of several hours do not take
into consideration the initial reaction and chemical kinetics
involved which have a bearing on whether the reaction with
the peptide is going to be linear or not throughout its
duration.
The high throughput kinetic proﬁling (HTKP) method
[26] was able to address some of the shortcomings of earlier
reactivity assays with respect to reaction times and the chem-
istry of electrophiles that do not adhere to pseudo-ﬁrst order
kinetics. Measurements of peptide depletion/reactivity were
done at several time points for varying initial concentrations
of the sensitizers, and compensations were made for the
“drowning out eﬀects” [26] and loss of test chemicals due
to evaporation [26]. While this presented a breakthrough in
termsofdeterminingmoreaccuraterateconstantsthatcould
be tied to LLNA potency of the electrophiles, determining
rates of rapidly reacting sensitizers such as benzoquinone
and nitrobenzyl bromide still presented challenges and the
rate constants for these sensitizers had to be estimated rather
than measured. The application of stopped ﬂow techniques
[11]tomeasuretherateconstantsoftheserapidelectrophile-
nucleophile interactions introduced a novel chemoassay
that was superior with respect to the detectable range of
electrophilic reactivity. Other confounders such as potential
loss of nucleophile due to evaporation and even oxidation
were eliminated ensuring the measurement of reaction rates
from solution kinetics. Using this technique, the modeling
and correlations of reactivity constants to LLNA data were
able to utilize measured rate constants instead of estimates.
Our current method utilizes the depletion of NBT with
the assumption that the electrophile-nucleophile reactions
are characterized by adduct formation. Peptide binding4 Journal of Allergy
studies [31], which have included characterization of the
chemical products formed, have noted oxidation of the
peptide thiol producing an apparent loss of parent peptide
whenever there was absence of adduct formation. The
buﬀered organic media precluded oxidation of nucleophile
to species other than the disulﬁdes of which the rate
would have been slower than the electrophile-nucleophile
reaction. We are currently evaluating an amine-based probe,
pyridoxylamine (PDA) that will better assess amine-selective
electrophiles. This assay, which captures adduct formation
without interference from side reactions like oxidations,
might be of greater utility than the previously reported
assayswherecomplicationsarosefromsidereactions.Several
advantages in screening for hapten potency by binding to
NBT and PDA include the ability to quickly obtain both
initial and overall binding rates for both extremely fast
or slow reactions, increased accuracy of rate constants,
analysis which can be conducted on relatively inexpensive
stopped-ﬂow spectrophotometers, and the ability to model
potential reaction mechanisms, competing mechanisms, and
intermediate products.
4.Nonelectrophilic Haptens
The allergenicityof nonelectrophilic compounds and metals,
which have not been shown to be metabolically bioactivated
cannot be explained by direct electrophile-nucleophile inter-
action chemistry. When the potential for chemicals to induce
mutations in Salmonella w a su s e da sas u r r o g a t ef o re l e c -
trophilicity [33], correlation of electrophilicity with occur-
rence of ACD in humans from 355 randomly chosen chemi-
calallergensdemonstratedthatonly30%–40%ofthecontact
allergens were electrophilic. Nonelectrophilic compounds
havebeenstudiedincludingthiolssuchastherubberacceler-
atorallergens,mercaptobenzothiazole(MBT),mercaptoben-
zothiazole disulﬁde (MBTS), zinc diethyldithiocarbamate
(ZDEC), and tetraethylthiuram disulﬁde (TETD). Metabolic
activation to electrophilic metabolites may account for the
potency of a portion of these allergens; however, hap-
tenation mechanisms other than electrophile-nucleophile
interactions have been proposed. Guinea pig studies with
MBT and several structural analogues demonstrated that
sensitization was most likely a result of protein haptenation
via disulﬁde formation [34]. ACD cases which have also
been reported for chemicals like diallyl disulﬁde [35]a n d
lipoicacid[36]whicharethiolsfurtherindicatethatdisulﬁde
formation may be a common mechanism for chemical thiol
haptenation. The conclusion that MBT/MBTS haptenates
proteins via disulﬁde formation was supported by enzyme
inhibition and protein-binding studies where binding of
MBTS to enzymes (reductases) and other protein cysteine
residues was through disulﬁde formation [37]. Bioactivation
of MBT, which could potentially lead to an electrophilic
hapten was not observed [37], suggesting that MBT is not
a metabolically activated prohapten. To date, there are no
reports of MBT bioactivation by cutaneous cytochrome
P450s (CYPs) enzymes.
TETDhasalsobeenshowntohaptenateproteinsthrough
the formation of disulﬁde linkages [38]. As a strong ligand,
TETD binds coordinatively to metalloproteins, the mecha-
nism by which it inactivates aldehyde dehydrogenase [39]
and anhydrases [40]. Whether the same properties (binding
and inactivating dehydrogenase) that make TETD a suitable
alcohol abuse deterrent apply to skin sensitization biology is
yet to be determined. If accessible, chemicals like TETD and
ZDEC (through transmetallation) will chelate the metal ions
in a porphyrin center. Absorbance measurements, dialysis
experiments, and mass spectrometry after haptenation of
zinc/copper-superoxide dismutase (SOD) with ZDEC indi-
cated that the DEC from ZDEC were strongly chelated to the
c o p p e ri o no nS O D[ 38, 41, 42]. The lack of binding between
ZDEC and the apoenzyme was conﬁrmatory of the chelation
chemistry being the probable mechanism of haptenation
[38]. It has to be noted though, that ZDEC and TETD,
unlike MBT, can potentially be metabolized to electrophilic
species,throughsulfoxidation[43],whichwouldthenhapte-
nate proteins through electrophile-nucleophile interactions.
Human cytochrome P450 enzyme that can metabolize the
thiocarbamates has been identiﬁed [43]. Contact allergens
may also undergo nonenzyme catalyzed, air oxidation to
electrophilic intermediates. Lepoittevin [44] suggested the
separate classiﬁcation term, prehapten, to refer to chemicals
that undergo nonenzymatic transformation to the active
form.
5. Metal Allergens
The formation of coordinate bonds has been touted as
the mechanism behind metal ion-induced allergies. Com-
monly encountered metal allergens are transition and trace
metals which include nickel, cobalt, chromium, beryllium,
platinum, and gold [45]. Binding of metals to proteins
stems from the polarized nature of the metal atoms which
allows them to accept electrons from electron rich ligands.
Metals are capable of forming geometrically, highly deﬁned
coordination complexes with four or six electron donors.
The electron donors are mainly nitrogen or oxygen in
amino acid side chains of appropriate proteins or peptides
[46]. The binding of nickel to albumins was shown to
have the capacity to stimulate Ni-reactive T cells in the
presence of appropriate antigen presenting cells (APC) [47–
49]. The comparable response of T cells to determinants
formed by hapten peptides in a major histocompatibility
complex- (MHC-) binding groove versus the Ni–MHC–
peptide complexes strongly suggested that the coordinate
binding is a feasible mechanism for metal-induced allergies
[50]. Thus metals represent nonclassical haptens in the sense
that coordinate bonds which form metal-protein complexes
are not suﬃciently strong to survive antigen processing that
classical haptens undergo. The binding of metals like Ni
to cell surface proteins like MHC would indicate a more
plausible mechanism as it bypasses intracellular antigen
processing steps. This type of protein binding would suggest
that sensitization to metals is protein independent as long as
thecellsurfaceproteinisabletochelatethemetalandpresent
it to T cells. This protein/peptide independence can also be
attributed to the observed cross-reactivity between diﬀerent
metal ions [51, 52] and in the case of Ni it was proposed thatJournal of Allergy 5
Ni may link T cell receptors (TCR) and MHC in a peptide-
independentmanner[51].Anothermechanismthathasbeen
postulated for metals, Ni in particular, is binding to speciﬁc
carrier proteins that ensure survival of the critical Ni-peptide
complex throughout the transport and processing through
the epidermis and dermis, and then transfer of the metal
to short-lived, high-aﬃnity coordination sites created within
certain TCR–MHC contact zones [49].
6. Pharmacological Interaction Mechanism
Additional allergenic compounds that are otherwise chemi-
cally inert (unable to directly haptenate proteins) have been
shown to cause lymphocyte proliferation [53] suggesting a
diﬀerent mechanism by which they are able to stimulate
TCR. The chemicals, which are usually drugs associated
with adverse hypersensitivity reactions, have been shown
to bind to the MHC on the basis of their conformation
rather than reactivity. This kind of binding, referred to as
pharmacologicalinteraction(p-i),islabileandmoreeﬀective
when it is on the MHC and within proximity of the TCR
[53]. Experiments that involved washing steps after binding
of the MHC proteins and before stimulation of T cells
resulted in lack of stimulation indicating that the weak
protein binding is reversible. Washing was ineﬀective with
chemicals that were covalently bound to MHC peptides.
Other evidence supporting the model for direct interaction
of the sensitizer with both TCR and the MHC includes the
kinetics of T-cell activation which happens much faster than
would be feasible if antigen processing was occurring. The p-
i concept has been used to explain hypersensitivity of drugs
such as lidocaine, sulfamethoxazole, mepivacaine, celecoxib,
carbamazepin,lamotrigine, andciproﬂoxacin[54–58]whic h
are not haptens/prohaptens but still elicit an immune
response because their conformation allows them to ﬁt into
theMHC-TCRsandwich.Thechemicalp-phenylenediamine
(PPD) has been shown to stimulate TCR via this model in
addition to its ability to haptenate proteins [59]. The large
number of TCR available (>1012)[ 53] makes it plausible that
some chemicals will have conformations that allow them to
associate with the TCRs.
7.Prohaptens
Prohaptens are chemicals that are not protein reactive unless
theyaremetabolicallyactivatedtoelectrophilicspecies.Ithas
also been proposed that prohapten chemicals that undergo
air oxidation to reactive species be classiﬁed separately
as prehaptens, but the criteria on when a chemical is
a pro- or prehapten is confusing [44]. Many chemicals
such as PPD, isoeugenol, and limonene are assigned to
the pro- or prehapten category on evidence indicating
that they are either metabolized or undergo air oxidation.
With an estimated one third of known skin sensitizers
needing metabolic or abiotic activation to react with skin
proteins [60], it is important that a clear distinction be
made between haptens and prohaptens. The recent emphasis
on alternative screening methods to avoid animal use for
screening of both contact and respiratory allergens depends
onidentiﬁcationofprohaptenmechanismstominimizefalse
negative classiﬁcation of sensitizing chemicals. While guinea
pig tests and the LLNA are able to identify prohaptens,
nonanimal assays have to include a metabolizing system
to bioactivate these otherwise nonsensitizing chemicals.
With animal-based assays, the lack of false negatives with
prohaptens attests to the fact that the skin is an important
site of metabolizing enzymes even though its metabolic
capabilityhasnotbeenfullycharacterized[61].Bioactivation
of prohaptens commonly involves oxidative processes, with
the cytochrome P450 system (CYPs) playing a major role
in the biotransformation of the majority of prohaptens to
sensitizers. CYP enzymes that have been detected at the
mRNA level in the skin include CYP1A1, 1B1, 2B6, 2E1, and
3A5 [62]. While the proteins were not shown, this mRNA
expression was consistent with expression levels that were
found for normal human epidermal keratinocytes (NHEKs)
and dermal ﬁbroblasts [63–65]. Other metabolic enzymes
identiﬁed in the skin include monooxygenases, dehydroge-
nases, esterases, amidases, and Phase II enzymes which are
mainly transferases [66, 67]. Keratinocytes have also been
shown to possess prohapten metabolizing capacity [63, 68].
To date, there have been few studies on the characterization
ofprohaptenbioactivationbyCYPenzymes.Prohaptensthat
have been studied include the polyaromatic hydrocarbons
(PAHs), cinnamic alcohol, carvone oxime, isoeugenol, and
diphenylthiourea [62, 69–72]. Once bioactivated to an
electrophilic species, haptenation of proteins proceeds via
one of the previously discussed mechanisms (Table 1).
Metabolic activation has so far proven to be the Achilles’
heel for many in vitro and in chemico assays. The need to
exhaustively interrogate the use of metabolic systems where
prohaptens are concerned has been discussed in detail [73].
Recent in vitro studies [62, 74, 75] have included metabolic
systems to detect prohaptens with marked success, but more
work needs to be done to identify metabolic systems that are
more representative of skin metabolism.
8.Protein-SelectiveHaptenationTargets:
The Diisocyanate-AlbuminExample
Exposure to diisocyanates in the workplace is one of the
leading causes of occupational asthma. It is hypothesized
that isocyanate acts as a hapten by reacting with protein
carriers via nucleophilic attack; however, the ultimate form
of these protein-isocyanate conjugates that functions as
allergens in vivo is, as yet, unknown. The diverse functional
groups present in proteins (amines, amides, thiols, alcohols,
carboxylicacids)presentalargenumberofpotentialreaction
sites for the diisocyanate (dNCO). However, previous studies
have suggested that under physiological conditions, these
are limited to N-terminal α-amines, the sulfhydryl group
of cysteine, the hydroxyl groups of serine and tyrosine,
the ε-amine of lysine, and the secondary amine of the
imidazole ring of histidine [76]. Understanding the products
formed by reaction of allergenic dNCOs such as methylene
diphenyldiisocyanate (MDI) and toluene diisocyanate (TDI)6 Journal of Allergy
with biological molecules is critical to understanding the
mechanisms by which these chemicals aﬀect living systems.
Tandem mass spectrometry performed on a quadrupole
time-of-ﬂight (qTOF) mass spectrometer [77] is particularly
well suited for the characterization of chemically modi-
ﬁed proteins. Proteins of interest may be digested with
a proteolytic enzyme (such as trypsin) and the resultant
peptides analyzed with high sensitivity and mass accuracy.
Because covalent modiﬁcation of an amino acid residue
results in a change in that residue’s mass, accurate mass
determination of the fragment ions produced by collision-
induced dissociation [78] allows unambiguous assignment
of the site of modiﬁcation. Such experiments have become
routine for the analysis of posttranslational modiﬁcations
such as acetylation, glycosylation, and phosphorylation,
among many others [79].
Recent eﬀorts in our laboratory [81, 90] and others
[80] have begun to focus on harnessing the power of
tandem mass spectrometry to determine how and where
dNCOs modify model peptides and proteins. Hydrolysis
of the isocyanate functional group to a primary amine
is a competing reaction under aqueous conditions. These
hydrolyzed isocyanate amines may then undergo nucle-
ophilic addition to another dNCO molecule. Therefore,
conjugation products observed upon reaction of dNCOs
withmodelpeptidesandproteinsinvitroresultsinacomplex
variety of diﬀerent reaction products, including intra- and
intermolecular crosslinking, dNCO self-polymerization, and
dNCO hydrolysis. Our initial study focused on determining
the site of dNCO modiﬁcation on model bioactive peptides
conjugated under aqueous conditions [81]. Analysis of these
conjugates by tandem mass spectrometry revealed that the
dNCO was bound preferentially to the N-terminal amine of
each of the peptides examined. Furthermore, when a peptide
with an N-terminal residue containing a side chain amine
(lysine, arginine) was reacted with dNCO, intramolecular
crosslinking with the side chain amine becomes competitive
with hydrolysis, however, the reactivity decreases as the
residue is displaced further from the N-terminus. The results
of this peptide study suggested agreement with a long-held
hypothesis that the N-terminal amine of protein chains is a
likely target for isocyanate conjugation [76, 82]. Studies of
the kinetics of isocyanate binding with protein functional
groups [83] determined that at pH 7, reaction with an N-
terminal amine should proceed approximately 100 times
fasterthantheε-amineofthelysinesidechain.Thediﬀerence
is due to the relative pKa of the two functional groups
(α-NH3
+ pKa ∼ 9v e r s u sL y sε-NH3
+ pKa ∼10.5), as dNCO
conjugation proceeds through the neutral –NH2 rather than
the charged –NH3
+ species.
9. Conclusion
Although tandem MS studies of dNCO-conjugated peptides
are useful for determining the diverse chemical species
produced when dNCO binds amino acids, they do not
produce the unique chemical microenvironments presented
by the complex three-dimensional structure of proteins. In
order to understand how dNCOs react in these complex
Table 2
Residue MDI TDI
Asp1∗ XX
Lys4∗ XX
Lys12 X X
Lys73 X X
Gln104 X
Lys106 X
Lys136 X X
Lys137∗ XX
Lys159 X
Lys190 X X
Gln196 X
Lys199∗ XX
Lys205 X
Lys212 X
Lys262∗ X
Lys274 X
Lys276 X
Lys281 X
Lys351∗ XX
Lys378 X
Lys402 X
Lys413∗ XX
Lys414∗ XX
Lys432∗ XX
Lys436∗ XX
Lys439∗ XX
Lys444∗ XX
Lys524 X X
Lys525∗ XX
Lys534 X
Lys536 X X
Lys541∗ XX
Lys545 X
Lys557 X
Lys560 X
Lys573 X
Lys574 X
∗MDI binding sites indentiﬁed in [80].
environments,studiesonmodelproteinsareessential.Serum
albumin is an appropriate model protein, as it is monomeric
and its sequence and three dimensional structure have been
well deﬁned. It is naturally abundant (35–50mg/mL in
serum), found in most tissues, and has been identiﬁed as
a target of dNCO binding in vivo [84–89]. Recently, our
laboratory completed an extensive analysis of the binding
sites of TDI on human serum albumin [90]. At high
(40:1 dNCO:protein) ratios, near-stoichiometric binding
was observed; TDI binds at thirty-seven sites on the protein,
including the N-terminal amine on aspartic acid at position
one and the side chain of thirty-four lysine residues. At lower
conjugation ratios (1:2 dNCO:protein), a small subset ofJournal of Allergy 7
(a) (b)
Figure 1: (a) Lysine residues observed bound to MDI and TDI on human serum albumin. (b) All lysine residues on human serum albumin.
Figure 2: Lysine residues reactive to TDI but not MDI.
these thirty-seven sites is conserved, with binding observed
at the N-terminus and four lysine residues, suggesting these
sites are preferred binding sites. Kristiansson and coworkers
[91] determined that at a tenfold molar excess, HHPA bound
to thirty-seven sites on human serum albumin, including the
N-terminal aspartic acid and thirty-six lysine residues.
Interestingly, all 59 lysine residues of human serum
albumin have been determined to be solvent accessible, but
only 37 are reactive toward TDI, while 19 are reactive toward
MDI (Hettick and Siegel, unpublished data). Human serum
albumin is a highly charged molecule, in part accounting
for its high solubility. For example, Figure 1 provides two
views of human serum albumin based on its crystal structure
[92]. In Figure 1(a), the lysine residues that bind MDI and
TDI are highlighted, whereas in Figure 1(b), all 59 lysine
residues are highlighted. Steric eﬀects are insuﬃcient to
explain the diﬀerence between accessibility and observed
binding. It is therefore likely that the microenvironment
of the binding site(s) determines whether or not a certain
lysineresidueisreactivetowardisocyanate.Lysine199,which
is known to bind hydrophobic anions such as aspirin and
benzyl penicillin, was also determined to be a predominant
binding site for both TDI and MDI. Gerig and Reinheimer
[93] determined that the pKa of the aspirin binding site
(later determined to be Lys199) of albumin was 7.9. These
authors hypothesized based on the reactivity of human
serum albumin with dinitroﬂuorobenzene that there exist
two lysines on HSA that have a pKa as low as 7.9. In addition,
Lys199 has been shown by molecular dynamics calculations
to be predominantly uncharged, undergoing proton transfer
with the nearby Lys195 [94]. This study elegantly suggests
the reason we observed dNCO bound to Lys199, and not the
nearby the Lys195. Other sites noted to be abundant binders
of dNCO, such as Lys439 and Lys525, have been observed to
undergo nonenzymatic glycosylation in vivo. Glycosylation
is generally observed to occur at lysine residues located near
another amino group, presumed to be charged [95]. Lys439
is located in a region with two other nearby lysine residues
(Lys432 and Lys436) and Lys525 is part of a dilysine motif.
More recently, we have begun an investigation to
compare the binding sites of TDI and MDI on serum
albumin under identical conditions (40:1 dNCO:HSA;
50mM NH4HCO3, pH 7.9). Under these conditions, MDI is
observed to bind to a subset of 19 of the 37 sites observed for
TDI(seeTable 2).Althoughitwouldbetemptingtoattribute
diﬀerencesinbindingbetweenTDIandMDItostericeﬀects,
as seen in Figure 2, many of the lysine residues that are
reactive toward TDI but not MDI are open and highly
accessible. We therefore hypothesize that the diﬀerence in
observed binding between TDI and MDI is attributable to
a combination of steric eﬀects and the increased reactivity
of TDI. The electron withdrawing character of the second
N=C=O group on the aromatic ring of TDI signiﬁcantly
increases the reactivity of the ﬁrst isocyanate. In contrast,
the reactivity of the isocyanate functional group(s) on MDI
is lower because the p-ethyl phenylisocyanate substituent
is less electron-withdrawing. Wisnewski and coworkers also
examined the reaction products between MDI and human
serum albumin by HPLC-MS/MS. Their data indicated
14 binding sites on albumin, including 12 lysine and 2
asparagine residues, in relatively good agreement with the
results presented in Table 2. In addition, these authors
suggested that the four “dilysine” (KK) motifs in human
serum albumin are important binding sites, and that MDI
shows reactive speciﬁcity for the second lysine. As discussed
previously, the ability of a lysine residue to transfer its proton8 Journal of Allergy
to a nearby lysine or histidine residue may, in fact, lead
to increased reactivity toward dNCOs. However, as dilysine
motifs account for 8 of 36 TDI binding sites and 6 of 19 MDI
binding sites, it is clear that two lysine residues in a “KK”
arrangement are not essential to binding.
It has been recognized for over 80 years that the ability
of a hapten to react to a protein was central to its ability
to produce allergic sensitization. Haptenation of a protein
can occur by multiple mechanisms (primarily electrophilic
attack) and is dependent on many factors such as chemical
properties, bioavailability, and site of exposure. Recent
studies have greatly expanded the knowledge in this area by
demonstrating that it is the rate at which an electrophilic
hapten reacts with a nucleophile center that is a central
determinant in its dermal sensitization potency. In addi-
tion, the chemical mechanism of binding (i.e., mechanistic
domain) also inﬂuences allergenic potency. These physical
chemical factors, however, have not been shown to be related
toskewingoftheimmunologicalresponsetowardTh1versus
Th2. Studies are currently utilizing modern proteomic mass
spectrometrytoidentifyhaptenbindingsitesonproteinsand
to identify speciﬁc hapten target proteins. It is possible that
the protein-speciﬁc factors may play a role in the ultimate
nature of the immune response.
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